Please login to the form below

Not currently logged in

Ridgeback Biotherapeutics

This page shows the latest Ridgeback Biotherapeutics news and features for those working in and with pharma, biotech and healthcare.

Merck & Co halts development of potential COVID-19 drug MK-7110

Merck & Co halts development of potential COVID-19 drug MK-7110

Also this week, Merck &Co and its development partner Ridgeback Biotherapeutics said the clinical development of its investigational COVID-19 antiviral therapy molnupiravir in hospitalised patients with COVID-19 would not ... Merck &Co and Ridgeback

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...